Oxervate (cenegermin-bkbj ophthalmic solution) — Medica

Initial criteria

• Patient has received < 8 weeks of treatment in the affected eye(s); AND
• Medication is prescribed by an ophthalmologist or optometrist

Reauthorization criteria

• Patient has received < 16 weeks (total) of treatment in the affected eye(s) per lifetime; AND
• Patient has a recurrence of neurotrophic keratitis; AND
• Medication is prescribed by an ophthalmologist or optometrist

Approval duration

8 weeks per affected eye(s)